Cochrane Review Group

Urology

69 systematic reviews in Urology ask 1,000 questions. 19.6% have no studies to answer them, 19.8% rest on very low certainty evidence and 21.9% reach moderate or high certainty.

Reviews

Questions

1,000

current versions

No studies

19.6%

Moderate or high

21.9%

No studies 196 · 19.6%Ungraded 33 · 3.3%Very low 198 · 19.8%Low 354 · 35.4%Moderate 206 · 20.6%High 13 · 1.3%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Search questions in Urology

Thinnest evidence

All no studies and very low questions

Question	Effect	Evidence	Status / GRADE
Topical corticosteroids vs placebo or no treatment Change in retractability score · boys up to 18 years old with phimosis Topical corticosteroids for treating phimosis in boys (2024) · Cochrane	no estimate extracted	2 studies · 177 participants	Very low
Serenoa repens in combination with other phytotherapy vs placebo or no intervention Quality of lifeMeasured by IPSS‐QoL score (range 0 to 6) · lower urinary tract symptoms due to benign prostatic hyperplasia Serenoa repens for the treatment of lower urinary tract symptoms due to benign prostatic enlargement (2023) · Cochrane	no estimate extracted	2 studies · 265 participants	Very low
ESWL vs RIRS Quality of life MCID varies by instrument. · people (>14 years) with kidney stones Extracorporeal shock wave lithotripsy (ESWL) versus percutaneous nephrolithotomy (PCNL) or retrograde… (2023) · Cochrane	no estimate extracted	3 studies · 214 participants	Very low
ESWL vs RIRS Complications MCID: 3% absolute difference · people (>14 years) with kidney stones Extracorporeal shock wave lithotripsy (ESWL) versus percutaneous nephrolithotomy (PCNL) or retrograde… (2023) · Cochrane	RR 0.93 [0.63, 1.36]	13 studies · 1305 participants	Very low
Potassium paraaminobenzoate vs placebo Outcomes ( · men with acute (maximum of 12 months) Peyronie's disease with no prior treatment and no evidence of calcified plaques… Non‐surgical therapies for Peyronie's disease (2023) · Cochrane	no estimate extracted	NR	No studies
Injectional interferon alpha‐2B vs saline Treatment‐related adverse effects · men with chronic (≥ 12 months) Peyronie's disease (single plaque) Non‐surgical therapies for Peyronie's disease (2023) · Cochrane	no estimate extracted	NR	No studies
Injectional interferon alpha‐2B vs saline Degree of penile curvature · men with chronic (≥ 12 months) Peyronie's disease (single plaque) Non‐surgical therapies for Peyronie's disease (2023) · Cochrane	no estimate extracted	1 study · 103 participants	Very low
Injectional interferon alpha‐2B vs saline Discontinuation from treatment · men with chronic (≥ 12 months) Peyronie's disease (single plaque) Non‐surgical therapies for Peyronie's disease (2023) · Cochrane	RR 0.63 [0.22, 1.76]	1 study · 117 participants	Very low
Injectional nicardipine vs saline Outcomes ( · men with chronic Peyronie's disease (plaques without calcification) Non‐surgical therapies for Peyronie's disease (2023) · Cochrane	no estimate extracted	NR	No studies
Injectional nicardipine vs saline Patient‐reported ability to have intercourse · men with chronic Peyronie's disease (plaques without calcification) Non‐surgical therapies for Peyronie's disease (2023) · Cochrane	no estimate extracted	NR	No studies
Injectional nicardipine vs saline Quality of life · men with chronic Peyronie's disease (plaques without calcification) Non‐surgical therapies for Peyronie's disease (2023) · Cochrane	no estimate extracted	NR	No studies
Injectional nicardipine vs saline Treatment‐related adverse effects · men with chronic Peyronie's disease (plaques without calcification) Non‐surgical therapies for Peyronie's disease (2023) · Cochrane	RR 2.82 [0.12, 66.62]	1 study · 62 participants	Very low

Reviews 69

Topical corticosteroids for treating phimosis in boys

Moreno, G, Ramirez, C, et al. · Cochrane Database of Systematic Reviews · 2024

Urology

Thinnest evidence

Reviews 69

Topical corticosteroids for treating phimosis in boys

Serenoa repens for the treatment of lower urinary tract symptoms due to benign prostatic enlargement

Extracorporeal shock wave lithotripsy (ESWL) versus percutaneous nephrolithotomy (PCNL) or retrograde intrarenal surgery (RIRS) for kidney stones

Non‐surgical therapies for Peyronie's disease

Totally tubeless, tubeless, and tubed percutaneous nephrolithotomy for treating kidney stones

Dose‐escalated radiotherapy for clinically localized and locally advanced prostate cancer

Percutaneous nephrolithotomy versus retrograde intrarenal surgery for treatment of renal stones in adults

Immunotherapy for advanced or metastatic urothelial carcinoma

First‐line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta‐analysis

Tranexamic acid for percutaneous nephrolithotomy

Prostatic arterial embolization for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia

Narrow band imaging versus white light cystoscopy alone for transurethral resection of non‐muscle invasive bladder cancer

Transurethral microwave thermotherapy for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia

Intravesical gemcitabine for non‐muscle invasive bladder cancer

Circumcision devices versus standard surgical techniques in adolescent and adult male circumcisions

Anticholinergics combined with alpha‐blockers for treating lower urinary tract symptoms related to benign prostatic obstruction

Degarelix for treating advanced hormone‐sensitive prostate cancer

Ginseng for erectile dysfunction

Selective serotonin re‐uptake inhibitors for premature ejaculation in adult men

Minimally invasive treatments for lower urinary tract symptoms in men with benign prostatic hyperplasia: a network meta‐analysis

Posterior musculofascial reconstruction in robotic‐assisted laparoscopic prostatectomy for the treatment of clinically localized prostate cancer

Blue versus white light for transurethral resection of non‐muscle invasive bladder cancer

Water for preventing urinary stones

Radical prostatectomy versus deferred treatment for localised prostate cancer

Intravesical Bacillus Calmette‐Guérin versus mitomycin C for Ta and T1 bladder cancer